The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Myeloma highlights: UK perspective
Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, from the Royal Marsden Hospital NHS Foundation Trust, London, UK, highlights some of the interesting results from various studies in multiple myeloma relevant to UK practice, including the GRIFFIN (NCT02874742) and Cassiopeia (NCT02541383) studies. In this video, Dr Pawlyn draws focus on the daratumumab and bortezomib, thalidomide, and dexamethasone (VTD) combination in the Cassiopeia study, as well as the methodology and results from the MUK Nine b (NCT03188172) study. Dr Pawlyn also discusses the potential use of novel therapies, including CAR-T and bispecific antibodies, which may change the future of upfront therapy for multiple myeloma patients in the UK. This interview took place at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Atlanta, 2021.
Disclosures
Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel support; Amgen: Honoraria; Celgene / BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Oncopeptides: Other
